Tirzepatide vs CJC-1295
Side-by-Side Comparison
| Attribute | Tirzepatide | Cjc 1295 |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Growth Hormone Secretagogue |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... |
| Evidence Rating | A — FDA Approved | D — Preclinical |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Research-only / Not approved for human use |
| Safety Profile | Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting; Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 2.5–15 mg/week, titrated every 4 weeks | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly |
| Frequency | Once weekly | Once daily (no DAC) or 2–3 times weekly (with DAC) |
| Molecular Weight | ~4813.5 g/mol | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol |
| Half-Life | ~5 days (116 hours) | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days |
Overview
Tirzepatide and CJC-1295 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Shared Research Applications
These peptides target different research areas. Tirzepatide focuses on Weight Management, Metabolic Health, while CJC-1295 targets Anti-Aging, Body Composition.
Safety Considerations
Tirzepatide: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Related Products
Related Research News
Is Tirzepatide Better Than Semaglutide for Weight Loss? Comparison
A comparison examines if Tirzepatide outperforms Semaglutide for weight loss. The two drugs are directly contrasted on this measure. This regulatory news covers the key question of superiority.
Daily Orforglipron Preserves Weight Loss After Semaglutide or Tirzepatide
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide. The medication supports maintenance of weight reduced during prior use of these treatments. Its once-a-day schedule aids in sustaining results from semaglutide or tirzepatide therapy.
FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide
The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.